Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses (2017 - 2025)

Anika Therapeutics (ANIK) has disclosed Other Accumulated Expenses for 14 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 38.82% to $468000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $468000.0, a 38.82% decrease, with the full-year FY2025 number at $468000.0, down 38.82% from a year prior.
  • Other Accumulated Expenses was $468000.0 for Q4 2025 at Anika Therapeutics, down from $750000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $17.3 million in Q3 2021 to a low of $338000.0 in Q4 2023.
  • A 5-year average of $2.3 million and a median of $608000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 1581.77% in 2021, then plummeted 97.14% in 2022.
  • Anika Therapeutics' Other Accumulated Expenses stood at $1.1 million in 2021, then tumbled by 51.84% to $510000.0 in 2022, then tumbled by 33.73% to $338000.0 in 2023, then surged by 126.33% to $765000.0 in 2024, then plummeted by 38.82% to $468000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Other Accumulated Expenses are $468000.0 (Q4 2025), $750000.0 (Q3 2025), and $641000.0 (Q2 2025).